Osmotica Pharmaceuticals (NASDAQ:OSMT) Coverage Initiated at Cantor Fitzgerald

Research analysts at Cantor Fitzgerald initiated coverage on shares of Osmotica Pharmaceuticals (NASDAQ:OSMT) in a research report issued to clients and investors on Friday, Price Targets.com reports. The brokerage set an “overweight” rating and a $6.00 price target on the stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 108.33% from the stock’s current price.

Separately, Zacks Investment Research raised Osmotica Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 14th.

Shares of NASDAQ:OSMT opened at $2.88 on Friday. The company has a market capitalization of $180.24 million, a PE ratio of -1.99 and a beta of 2.69. Osmotica Pharmaceuticals has a 1 year low of $2.70 and a 1 year high of $6.49. The business has a fifty day moving average price of $3.47 and a two-hundred day moving average price of $3.27.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last issued its quarterly earnings data on Monday, August 16th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.14). The company had revenue of $11.51 million for the quarter, compared to analysts’ expectations of $34.50 million. Osmotica Pharmaceuticals had a negative return on equity of 43.86% and a negative net margin of 71.48%. On average, sell-side analysts forecast that Osmotica Pharmaceuticals will post -0.89 EPS for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Walleye Trading LLC purchased a new position in shares of Osmotica Pharmaceuticals in the first quarter worth $33,000. Barclays PLC grew its holdings in shares of Osmotica Pharmaceuticals by 147.4% in the first quarter. Barclays PLC now owns 10,934 shares of the company’s stock worth $36,000 after acquiring an additional 6,515 shares during the period. Royce & Associates LP bought a new stake in shares of Osmotica Pharmaceuticals in the first quarter worth $39,000. Public Employees Retirement System of Ohio bought a new stake in shares of Osmotica Pharmaceuticals in the first quarter worth $42,000. Finally, Zebra Capital Management LLC bought a new stake in shares of Osmotica Pharmaceuticals in the first quarter worth $79,000. Institutional investors own 7.71% of the company’s stock.

About Osmotica Pharmaceuticals

Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women’s health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs.

Featured Article: The limitations of an equal weight rating

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.